Klaria Pharma
Klaria Interim Report Q3 2024
Third quarter of 2024
The group in total
- Net sales 0.0 MSEK (0.6 MSEK)
- Other income 0.0 MSEK (0.0 MSEK)
- R&D expenses for the quarter amounted to 1 MSEK (7.4 MSEK)
- Profit after tax amounted to -7.9 MSEK (-10.8 MSEK)
- Earnings per share for the quarter amounted to -0.06 SEK (-0.10 SEK)
- Cash flow from operating activities amounted to -3.8 MSEK (-7.3 MSEK)
- Liquid assets on the balance sheet date amounted to 0.5 MSEK (2.3 MSEK)
- Equity as of September 30 amounted to 12.9 MSEK (50.7 MSEK)
The period January- September 2024
The group in total
- Net sales 0.0 MSEK (7.1 MSEK)
- Other income 0.0 MSEK (0.2 MSEK)
- R&D expenses for the quarter amounted to 2.5 MSEK (23.0 MSEK)
- Profit after tax amounted to -32.2 MSEK (-26.3 MSEK)
- Earnings per share for the period amounted to -0.26 SEK (-0.27 SEK)
- Cash flow from operating activities amounted to -13.2 MSEK (-18.6 MSEK)
| Datum | 2024-11-21, kl 15:00 |
| Källa | Cision |
SAVR är investeringsplattformen som utmanar branschen och gör det både enklare och roligare att investera. Betala aldrig för mycket! Alla aktier och ETF:er från 1 kr, och få upp till 50 % rabatt på alla fonder. Automatiskt courtage och samma enkla prismodell på alla marknader.